Classys Inc. · KRX:214150
Classys — J.P. Morgan Healthcare Conference 2025
22 slides from Classys's conference presentation, Jan 16, 2025
Slide 1: Expanding Possibilities in Medical Aesthetics
Expanding Possibilities in Medical Aesthetics J.P. Morgan Healthcare Conference January 16, 2025 Presenters: Seung Han Baek, Chief Executive Officer Laehee Kim, Chief Marketing Officer
Slide 2: Disclaimer
Disclaimer This material has been prepared by Classys (the “company”) for the purpose of providing information in a presentation that will be made for investors. Please be informed that transferring, copying, or re-distributing this document to others is prohibited. Attendance at this presentation i
Slide 3: Today's Agenda
Today’s Agenda I. Our Essence: Who We Are II. Expanding Horizons: Where We Play III.Redefining the Game: What We Do Differently IV.Blueprint for Tomorrow: How We Will Grow 3
Slide 4: Our Mission & Vision
Our Mission & Vision OUR MISSION To help people around the globe discover their best, most natural selves through relentless customer-centric innovation. VISION 2030 To be the world’s #1 provider of medical aesthetic platform. (Revenue >$1B, OPM >50%) 4
Slide 5: Classys at a glance
Classys at a glance 2018-2023 CAGR 31% 38,000 Global #1 Installed Base Revenue Growth around 70 countries 2018-2023 CAGR Consumables Sales Growth 39% ㅍ 5M Ultraformer Treatments / year Consumables sales share 43% 300 shots / treatment 2018-2023 CAGR EBITDA Growth 39% #1 Brand Power EBITDA >50% since
Slide 6: Today's Agenda
Today’s Agenda I. Our Essence: Who We Are II. Expanding Horizons: Where We Play III.Redefining the Game: What We Do Differently IV.Blueprint for Tomorrow: How We Will Grow 6
Slide 7: High-growth Aesthetic EBD market projected to expand at 20% CAGR
We operate in a robust, high-growth Aesthetic EBD1)(Energy-Based Device) market, projected to expand at a 20% CAGR, fueled by strong demand. Global Aesthetic EBD Market Size & Growth Market Growth Drivers $9.7B Patients • Rising acceptance of preventive EBD treatments CAGR 20% • Social media boostin
Slide 8: EBD adoption expands from specialists to the mass market
As EBD adoption expands from medical specialists to the mass market, customer demand and market penetration soar. Market Segmentation & Adoption Flow Treatment Efficacy by Indication Aesthetic EBD Botulinum Laser Filler Toxin HIFU MRF MNRF Medical Specialists Lifting H M M L (Derms/Plastics) Rejuven
Slide 9: Clinic/MedSpa and patient penetration remain low in most countries
Clinic/MedSpa and patient penetration remain low in most countries, presenting significant opportunities in major markets like the U.S. ’24E Clinic/MedSpa Penetration1) ’30F Botulinum Toxin (’24E) HIFU MRF MNRF 100% 100% 100% 80% 80% 80% 60% 60% 60% 40% 40% 40% 20% 20% 20% 0% 0% 0% U.S. EUR CN KR BR
Slide 10: Today's Agenda
Today’s Agenda I. Our Essence: Who We Are II. Expanding Horizons: Where We Play III.Redefining the Game: What We Do Differently IV.Blueprint for Tomorrow: How We Will Grow 10
Slide 11: Products driven by innovation and understanding of customer pain points
Our products are driven by a pursuit of innovation and a deep understanding of customer pain points, redefining how challenges are addressed. Patient Pain Points Clinic/MedSpa Pain Points Our Aesthetic EBD Blockbusters Ultraformer (HIFU) “Painful procedure” “Expensive costs” Leading HIFU brand with
Slide 12: Complete range of medical aesthetic technologies
We offer a complete range of medical aesthetic technologies, including HIFU, MRF, MNRF, and laser platforms, many with consumables. HIFU MNRF & Laser Consumables 43% Platform 54% Consumer Device & Topicals 3% Ultraformer MPT Secret RF Reepot CuRas HIFU 23% MRF Other Platforms MRF 15% Other MNRF Plat
Slide 13: Installed base driving consumables revenue, strong GM and OPM
We prioritized democratizing access with our growing global installed base driving consumables revenue, strong GM, and OPM. Consumables & OPM Trends EBRP(Energy-Based Recurring Platform) Model 51%53%51% 60% 80% 50% 49%50% 70% Classys EBRP Typical model 37% 60% 49% 40% Technology Aesthetic EBD Other
Slide 14: Rapid global growth with untapped key markets
We've experienced rapid global growth, yet substantial opportunities remain untapped in key markets like the U.S., EUR, and China. Sales by Region Sales of Top 4 Countries (Unit: Million USD) (Unit: Million USD) CAGR Korea Brazil Thailand Japan Korea CAGR CAGR CAGR CAGR CAGR 42% 42% 83% 146% 28% 33%
Slide 15: Products supported by rigorous clinical evidence
Our products are supported by rigorous clinical evidence from leading studies conducted globally, ensuring proven effectiveness and trusted results. Sound Scientific Leadership 50+ Clinical papers 200+ Key opinion leaders published to date worldwide 5,000 Attendees 1,000 Training certificates take p
Slide 16: Strong Marketing Expertise
Our marketing initiatives, both clinics and patients across the globe, have driven rapid growth, solidifying our position as a leader in the industry. Strong Marketing Expertise Strong NPI1) rollout Effective ATL2) & BTL3) marketing GTM expertise for each NPI Large scale ads & targeted user meetings
Slide 17: Today's Agenda
Today’s Agenda I. Our Essence: Who We Are II. Expanding Horizons: Where We Play III.Redefining the Game: What We Do Differently IV.Blueprint for Tomorrow: How We Will Grow 17
Slide 18: Evolving product portfolio and robust NPI pipeline
Our evolving product portfolio is supported by a robust pipeline of NPIs, reflective of market insights to address the needs of our customers. ~ 2023 2024 2025E 2026E 2027E Lifting & Tightening Pigmentation Tightening & Resurfacing Rejuvenation Lifting & Tightening Upgrade Every 4-5 years Ultraforme
Slide 19: Targeting larger markets: U.S., China and EUR
We are now strategically targeting larger markets, including the U.S., China, and EUR, to accelerate global expansion. China U.S. 2026- 2024- EUR 2025- ▪ Volnewmer in 2026 ▪ Everesse (Volnewmer) ▪ Ultraformer MPT in 2027 in 4Q24 ▪ Ultraformer MPT and ▪ Secret Max in 2028 ▪ Secret Max in 3Q25 ▪ Ultra
Slide 20: Goal of reaching $1B by 2030 with 30% CAGR
With a bold goal of reaching $1B by 2030, we are set to achieve a 30% CAGR over the next six years. HIFU / MRF / MNRF Other B2B / B2C (77% of total growth) (23% of total growth) $1B $0.2B $0.1B $0.2B $0.3B $0.2B 1) Current Expansion & Entry: Accelerating Growth: Driving Growth in NPI 2030E Top 3 tar
Slide 21: In Closing…
In Closing… The aesthetic EBD market projected to grow at a 20% CAGR from ’24–’30. Our EBRP business model allows us to sustain a strong growth & margin profile. We will expand into new territories – U.S., Europe, China. We will continue to innovate new products to meet the 5-year replacement cycle.
Slide 22: For inquiries, please contact us at ir@classys.com
For inquires, please contact us at: ir@classys.com